Literature DB >> 18322079

A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS.

Seija Lehnardt1, Eckart Schott, Thorsten Trimbuch, Dinah Laubisch, Christina Krueger, Gregory Wulczyn, Robert Nitsch, Joerg R Weber.   

Abstract

Infection, ischemia, trauma, and neoplasia elicit a similar inflammatory response in the CNS characterized by activation of microglia, the resident CNS monocyte. The molecular events leading from CNS injury to the activation of innate immunity is not well understood. We show here that the intracellular chaperone heat shock protein 60 (HSP60) serves as a signal of CNS injury by activating microglia through a toll-like receptor 4 (TLR4)-dependent and myeloid differentiation factor 88 (MyD88)-dependent pathway. HSP60 is released from CNS cells undergoing necrotic or apoptotic cell death and specifically binds to microglia. HSP60-induced synthesis of neurotoxic nitric oxide by microglia is dependent on TLR4. HSP60 induces extensive axonal loss and neuronal death in CNS cultures from wild-type but not TLR4 or MyD88 loss-of-function mutant mice. This is the first evidence of an endogenous molecular pathway common to many forms of neuronal injury that bidirectionally links CNS inflammation with neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322079      PMCID: PMC6671170          DOI: 10.1523/JNEUROSCI.4760-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  120 in total

1.  Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling.

Authors:  Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  Heat shock proteins as biomarkers for the rapid detection of brain and spinal cord ischemia: a review and comparison to other methods of detection in thoracic aneurysm repair.

Authors:  James G Hecker; Michael McGarvey
Journal:  Cell Stress Chaperones       Date:  2010-08-30       Impact factor: 3.667

4.  Alcohol-induced interactive phosphorylation of Src and toll-like receptor regulates the secretion of inflammatory mediators by human astrocytes.

Authors:  Nicholas A Floreani; Travis J Rump; P M Abdul Muneer; Saleena Alikunju; Brenda M Morsey; Michael R Brodie; Yuri Persidsky; James Haorah
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-09       Impact factor: 4.147

Review 5.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

6.  Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson's disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons.

Authors:  Can Zhao; Hui Li; Xian-Jing Zhao; Zheng-Xia Liu; Ping Zhou; Ying Liu; Mei-Jiang Feng
Journal:  Neurochem Res       Date:  2016-01-12       Impact factor: 3.996

7.  Pathophysiology and treatment of bacterial meningitis.

Authors:  Olaf Hoffman; R Joerg Weber
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 8.  Microglial phenotype and adaptation.

Authors:  B J L Eggen; D Raj; U-K Hanisch; H W G M Boddeke
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-25       Impact factor: 4.147

9.  The expression and release of Hsp60 in 6-OHDA induced in vivo and in vitro models of Parkinson's disease.

Authors:  Mei jiang Feng; Ling Zhang; Zhengxia Liu; Ping Zhou; Xiang Lu
Journal:  Neurochem Res       Date:  2013-08-14       Impact factor: 3.996

Review 10.  Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.